Sound Pharmaceuticals said today it has filed an application to run a clinical trial of an experimental drug for hearing loss caused by cancer chemotherapy. The privately held Seattle biotech company said it plans to test the compound, ebselen, in patients with advanced lung cancer and head and neck tumors who received platinum-based chemotherapy. It is the second clinical program for Sound, which is testing the ebselen product with the U.S. Navy to prevent and treat hearing loss caused by loud noises.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
